Axsome Therapeutics, Inc.
0 products tracked · names used in filings: Axsome Therapeutics, Inc.
Upcoming milestones
AXS-12: PDUFA target action date (cataplexy in narcolepsy)
Axsome Therapeutics, Inc. (AXSM); reboxetine; NDA; status: set; "The PDUFA target action date is May 1, 2027."; filed 2026-11-02 · source
Recent milestones
AXS-05: PDUFA target action date (Alzheimer's disease agitation)
Axsome Therapeutics, Inc. (AXSM); dextromethorphan-bupropion; sNDA; status: set; "…$124.8 million, respectively, representing 40% and 32% year-over-year growth SYMBRAVO ® 4Q and full year 2025 net product sales of $4.1 million and $6.6 million, respectively sNDA for AXS-05 for the treatment of Alzheimer’s disease agitation granted Priority Review with PDUFA target action date of April 30, 2026…"; filed 2026-02-23 · source
Products
No products recorded.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.